Best Momentum Stocks to Buy for September 17th

Zacks highlighted Motorsport Games, Assembly Biosciences and MGIC Investment as Zacks Rank #1 momentum stocks for September 17. Current-year consensus earnings estimates rose 30.4% for Motorsport Games, 20.0% for Assembly Biosciences and 6.2% for MGIC over the past 60 days; Motorsport Games shares gained 8.6% over three months versus a 0.8% S&P 500 increase. The item is analyst-driven stock-selection commentary and is likely to have limited broad market impact.

Analysis

This is not a durable information event: estimate-revision screens can attract short-lived retail and quant flows, but they do not establish earnings quality. MSGM is the weakest institutional candidate because limited liquidity and a small operating base can make both consensus changes and momentum signals mechanically unstable; any price spike is more likely to widen execution risk than improve fundamental value. Avoid treating the publication itself as a catalyst.

ASMB should trade on clinical and partnering milestones, not model revisions. Its risk/reward is binary and financing-sensitive: absent a disclosed runway sufficient to reach the next value-inflecting dataset, positive estimate changes have little bearing on dilution-adjusted equity value. The relevant second-order read-through is limited; diversified large-cap biotech is unlikely to move on company-specific developments.

MTG is the only name with a potentially investable macro linkage, but the key variable is not near-term EPS momentum. Mortgage insurers rerate when the market gains confidence that new-insurance-written volumes, persistency, and credit losses can remain favorable simultaneously; lower mortgage rates can improve origination volume but also reduce persistency as borrowers refinance. Over the next 1-3 months, relative performance versus RDN, ESNT, and NMIH should be driven by delinquency trends, capital-return capacity, and reserve development rather than this screen-driven attention.

Contrarian view: the consensus may overvalue upward estimate revisions in thinly covered companies while underweighting the asymmetry in mortgage credit. A modest deterioration in unemployment or home prices can cause a disproportionate multiple reset for mortgage insurers, even before realized claims rise. Conversely, if credit remains benign and buybacks continue, MTG's capital return can matter more than incremental earnings revisions over 6-18 months.

Key Decisions for Investors

• No trade in MSGM on this signal; restrict any exposure to event-driven liquidity windows only. Reassess only if average daily dollar volume, cash runway, and independently verified revenue guidance support institutional execution; invalidate any momentum thesis on a break below the prior 20-day low.
• Keep ASMB on a catalyst watchlist rather than initiate on estimate revisions. Consider a defined-risk long only after confirmation of next clinical-data timing, cash runway through that readout, and option liquidity; failure to secure runway without material dilution is thesis-negative.
• Monitor MTG versus RDN, ESNT, and NMIH for a 1-3 month relative-value long. Initiate MTG/RDN only if MTG's valuation discount persists despite comparable delinquency performance and announced capital return; stop if MTG's delinquency or reserve development deteriorates materially versus peers.
• Use the mortgage-rate path and housing-credit data as gating indicators: a sustained decline in mortgage rates without a rise in cure rates/refinancing-related persistency pressure is constructive for the group, while rising unemployment, falling home prices, or widening mortgage-credit spreads warrants reducing all MI exposure.